Evaluation of TP53/PIK3CA mutations using texture and morphology analysis on breast MRI

Abstract

PurposeSomatic mutations in TP53 and PIK3CA genes, the two most frequent genetic alternations in breast cancer, are associated with prognosis and therapeutic response. This study predicted the presence of TP53 and PIK3CA mutations in breast cancer by using texture and morphology analyses on breast MRI. Materials and methodsA total of 107 breast cancers (dataset A) from The Cancer Imaging Archive (TCIA) consisting of 40 TP53 mutation cancer and 67 cancers without TP53 mutation; 35 PIK3CA mutations cancer and 72 without PIK3CA mutation. 122 breast cancer (dataset B) from Seoul National University Hospital containing 54 TP53 mutation cancer and 68 without mutations were used in this study. At first, the tumor area was segmented by a region growing method. Subsequently, gray level co-occurrence matrix (GLCM) texture features were extracted after ranklet transform, and a series of features including compactness, margin, and ellipsoid fitting model were used to describe the morphological characteristics of tumors. Lastly, a logistic regression was used to identify the presence of TP53 and PIK3CA mutations. The classification performances were evaluated by accuracy, sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV). Taking into account the trade-offs of sensitivity and specificity, the overall performances were evaluated by using receiver operating characteristic (ROC) curve analysis. ResultsThe GLCM texture feature based on ranklet transform is more capable of recognizing TP53 and PIK3CA mutations than morphological feature, especially for the TP53 mutation that achieves statistically significant. The area under the ROC curve (AUC) for TP53 mutation dataset A and dataset B achieved 0.78 and 0.81 respectively. For PIK3CA mutation, the AUC of ranklet texture feature was 0.70. ConclusionTexture analysis of segmented tumor on breast MRI based on ranklet transform is potential in recognizing the presence of TP53 mutation and PIK3CA mutation.